It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2023: Some negative, some positive, but we learned from all!
Feel free to add more & retweet & tag
This is not an exhaustive list!
@OncoAlert @danafarber @DanaFarber_GU
#OnwardFor2024
1/#COSMIC-313 phase 3 trial shows ⬆️PFS with Cabozantinib plus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic #RCC presented @myESMO #ESMO22
@motzermd @NEJM @tompowles1 @AlbigesL @DrDanielHeng @FabioSchutz78 @BurottoMauricio
COI: trial PInejm.org/doi/full/10.10…
2/In HRR-def #mCRPC: adding talazoparib to enza as 1L improved rPFS(HR=0.45), #PSA-progression, time to chemo, RR, could ⬆️OS (HR=0.69, immature) from Ph 3 #TALAPRO-2 trial. Presented #GU23 @ASCO
@neerajaiims @NatureMedicine #Fizazi @AzadOncology
nature.com/articles/s4159…
3/ Addition of Nivolumab to Gem/Cis #chemotherapy as a 1L unresectable or #mUC significantly improves OS (HR=0.78) and PFS (HR=0.72). Presented #ESMO23 @myESMO
@MichvdHeijden @sonpavde @MattGalsky @NEJM @tompowles1
nejm.org/doi/full/10.10…
4/Encouraging data from phase3 #THOR trial: in patients with refractory post-PD1 #mUC with #FGFR3/2 alt resulted in ⬆️OS and PFS with ⬇️ TRAEs compared to chemotherapy.
@y_loriot @NEJM @GustaveRoussy #Siefker-Radtke
nejm.org/doi/full/10.10…
5/More therapeutic option for #nccRCC! Results from phase 2 trial #KEYNOTEB61 support the use of Pembro+Lenvatinib as 1L therapy for patents with previously untreated advanced #nccRCC
@AlbigesL @ChungHanLee3 @TheLancetOncol @myESMO
thelancet.com/journals/lanon…
6/For patients with high-risk biochemical recurrent #PC: phase 3 #EMBARK shows that enzalutamide plus leuprolide and enzalutamide monotherapy were superior to leuprolide alone in term of metastasis-free survival!
@SFreedlandMD @nealshore @NEJM
nejm.org/doi/full/10.10…
7/ Encouraging prelim findings from #AMG-509(xaluritamig): T cell engager targeting #STEAP1 immunotherapy in patients with #mCRPC improves clinical outcomes. Phase I safe and tolerable.
#kelly @LenAppleman @CD_AACR
aacrjournals.org/cancerdiscover…
8/This phase 2 trial demonstrated that #NAC in high-grade #UTUC was tolerated, and lead to ⬆️PFS and OS of responders compared to non responders. Kudos to the exceptional team @MSKCancerCenter GU Center @DrRosenbergMSK
@JCO_ASCO @bbmdmsk #Coleman #Bajorin
ascopubs.org/doi/pdf/10.120…
9/More on #RCC from#CONTACT-03 led by @montypal : 1st trial assessing #rechallenging with #ICI in #RCC with #anti-PDL1 didn’t show improvement of PFS and OS , w/ ⬆️toxicity.
@montypal @tompowles1 @TheLancet @ASCO @AlbigesL presented #ASCO23 @ASCO
thelancet.com/journals/lance…
10/Promising data from this phase1 trial evaluating☢️ radioligand therapy with #ICI in patients with #mCRPC:a single priming dose of #LuPSMA followed by pembro maintenance was safe with confirmed OR.
@lawfong @thomashopemd @TheLancetOncol @myESMO
thelancet.com/journals/lanon…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.